ZLN005 is a PGC-1 Transcriptional Regulator, which shoed some beneficialfEffects on diabetic db/db mice. ZLN005 increased fat oxidation and improved the glucose tolerance, pyruvate tolerance, and insulin sensitivity of diabetic db/db mice. Hyperglycemia and dyslipidemia also were ameliorated after treatment with ZLN005. Our results demonstrated that a novel small molecule selectively elevated the expression of PGC-1 in myotubes and skeletal muscle and exerted promising therapeutic effects for treating type 2 diabetes.
For research use only. We do not sell to patients.